Seeking Alpha

Baxter gets a nudge downward

  • Goldman Sachs removes Baxter International (BAX) from its Conviction List and lowers its PT from $83 to $77 but maintains its Buy recommendation. Since the firm added BAX to its Americas CL in August it is off 7.7% versus the S&P 500's 8.5% gain.
  • Analyst David Roman cites a higher risk profile due to heightened competition in the plasma business.
  • Investors appear unconcerned. Shares are up a fraction in early trading.
Comments (1)
  • DavidBaird
    , contributor
    Comments (76) | Send Message
    My thought is that Goldman's price target of $83 might have been a little optimistic to begin with.....
    17 Mar, 07:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector